2. Academic Validation
  3. Silencing of S100A11 attenuates murine metabolic dysfunction-associated steatohepatitis

Silencing of S100A11 attenuates murine metabolic dysfunction-associated steatohepatitis

  • NPJ Gut Liver. 2025;2(1):32. doi: 10.1038/s44355-025-00044-w.
P V Daniel # 1 2,  Gyanendra Puri # 1,  Yixing Luo # 1 3,  Naresh Golla 1 4,  Takahito Nishihara 1 5,  Hanna Erickson 1,  George Marek 1,  Nagaswaroop Kengunte Nagaraj 6,  Davide Povero 1,  Amy S Mauer 1,  Jun Liu 7,  Harmeet Malhi 1
Affiliations

Affiliations

  • 1 Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905 US.
  • 2 Present Address: Division of Medical Research, SRM Medical College Hospital and Research Center, SRM Institute of Science and Technology, Kattankulathur, 603203 India.
  • 3 Present Address: Department of Gastroenterology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006 China.
  • 4 Division of Cardiovascular Diseases, Center for Regenerative Medicine, Mayo Clinic, Rochester, MN 55905 US.
  • 5 Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, 852-8501 Japan.
  • 6 Department of Quantitative Health Sciences, Computational Biology, Mayo Clinic College of Medicine & Science, Rochester, MN 55905 USA.
  • 7 Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine & Science, Rochester, MN 55905 USA.
  • # Contributed equally.
PMID: 41357846 DOI: 10.1038/s44355-025-00044-w
Abstract

Metabolic dysfunction-associated steatohepatitis (MASH) is characterized by Insulin resistance and impaired hepatic metabolism, which lead to steatosis and lipotoxicity. S100A11, an alarmin upregulated in MASH, promotes steatosis in vitro, but its role in vivo remains unclear. We hypothesized that S100A11 drives MASH by upregulating hepatic lipid synthesis. Using whole-body S100a11 knockout (S100a11 -/- ) mice on a MASH-inducing diet, we found S100a11 deficiency reduced steatosis, inflammation, and fibrosis. Hepatotropic AAV8-mediated silencing of S100a11 confirmed these findings. Bulk RNA Sequencing with Ingenuity Pathway Analysis revealed dysregulated carbohydrate and lipid metabolism in S100a11 -/- livers, including downregulation of Hexokinase 2 (Hk2). Since hexokinases regulate glucose flux into downstream metabolic processes, we overexpressed HK2 in S100a11 -/- mice, which was sufficient to increase steatosis. Further, palmitate-induced HK2 upregulation required S100A11 in a human hepatocyte cell line. These studies identify HK2 as a downstream target of S100A11, both of which are potential therapeutic targets for MASH.

Keywords

Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis.

Figures
Products